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Abstract  
Context. Pediatric palliative care randomized controlled trials (PPC-RCTs) are 
uncommon. 
Objectives. To evaluate the feasibility of conducting a PPC-RCT in pediatric cancer 
patients.  
Methods.  This was a cohort study embedded in the Pediatric Quality of Life and 
Evaluation of Symptoms Technology (PediQUEST) Study (NCT01838564). This multicenter 
PPC-RCT evaluated an electronic patient-reported-outcomes system. Children ≥2-years-old, with 
advanced cancer, and potentially eligible for the study were included. Outcomes measured were: 
pre-inclusion attrition: patients not approached, refusals; post-inclusion attrition: drop-out, 
elimination, death, and intermittent attrition (missing surveys) over nine months; child/teenager 
self-report rates; and reasons to enroll/participate. 
Results. Over five years, of the 339 identified patients, 231 were eligible (in 22 we could 
not verify eligibility); 87774 eligible patients were not approached and 43 declined participation. 
Patients not approached were more likely to die or have brain tumors. We enrolled 104 patients. 
Average enrollment rate was one patient/site/month; shortening follow-up from nine to three 
months (with optional re-enrollment) increased recruitment by 20%. Eighty-seven patients 
completed the study (24 died) and 17 dropped out. Median intermittent attrition was 41% in the 
first 20 weeks of follow-up, and over 60% in the eight weeks preceding death. Child/teenager 
self-report was 94%. Helping others, low burden procedures, incentives, and staff attitude were 
frequent reasons to enroll/ participate.  
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Conclusion. A PPC-RCT in children with advanced cancer was feasible, post-inclusion 
retention adequate; many families participated for altruistic reasons. Strategies that may further 
PPC-RCT feasibility include: increasing target population through large multicenter studies, 
approaching sicker patients, preventing exclusion of certain patient groups, and improving data 
collection at end of life. 
Key Words: pediatrics, pediatric oncology, supportive care, feasibility, attrition, end-of-life 
care, patient-reported outcomes, randomized controlled trial, palliative care 
Running Head: Feasibility of the PediQUEST RCT 
Trial Registration:  clinicaltrials.gov Identifier: NCT01838564 
Accepted for publication: December 23, 2014. 
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Introduction  
Although the need for high quality intervention research in pediatric palliative care has 
long been recognized as a priority (1-4), such studies are uncommon and difficult to accomplish 
(5). Research in children with advanced illness entails dealing with small and heterogeneous 
populations, highly sensitive topics, and complex outcomes measurement (i.e., developmentally 
adapted and inclusive of parents) (6, 7). These requirements add to the barriers to palliative care 
investigations (8). 
Systematic reviews have identified accrual, patient retention, and valid outcome 
measurement as the leading obstacles to adult palliative care randomized controlled trials (RCTs) 
(9-11). Reasons for the low enrollment rates include patients being either too overwhelmed or 
dying before accrual, and caregivers’ or clinicians’ beliefs that the ill patient cannot withstand 
participation or that study procedures are too burdensome or not worth the patient’s time (12-15). 
Furthermore, palliative care studies inevitably have high attrition rates (8). Participation 
deterrents include death, illness progression, and drop-out or intermittent missing data because of 
patient or family request, change in treatment facility or clinician, or overwhelmed caregivers 
(14, 16-18). Despite these challenges, a recent systematic review found that participation in end-
of-life care research is a positive experience, with most participants reporting direct benefits or 
comfort, and viewing participation as a means to contribute to care improvement (19).  
Pediatric palliative care (PPC) RCTs are scarce. Four studies were identified; three 
evaluated telemedicine interventions (5, 20, 21),  two of which were not completed because of 
low accrual, and the remaining one assessed an advanced care planning intervention (22). RCTs 
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are needed to increase the palliative care evidence base but guidance on how to effectively 
conduct them is scant (23).  
We sought to assess the feasibility of conducting a PPC RCT in children with cancer that 
advanced beyond initial treatment. The Pediatric QUality of life and Evaluation of Symptoms 
Technology (PediQUEST) Study evaluated the effect of an electronic patient- reported outcomes 
system on child distress(24). Feasibility was concurrently appraised. We describe the different 
sources of data loss, or attrition, from the moment patients were identified through the end of 
follow-up, and families’ views on participation at study entry and exit. 
Methods  
The PediQUEST Study was a pilot parallel 1:1 RCT conducted at three large U.S. 
pediatric cancer centers from December 2004 to December 2009. Methods described below 
pertain to the feasibility study. RCT methods have been described elsewhere (24) and are 
summarized in Fig. 1.  
Design and Participants 
This was a cohort study embedded in the PediQUEST pilot RCT.  All children were 
identified as potentially eligible for the PediQUEST Study, regardless of their participation 
status. The study was approved by the institutional review boards (IRBs) of participating sites. 
Study Procedures 
Attrition was defined following Howard (25) as “any data loss occurring during the 
study” and classified as: 1) pre-inclusion attrition, i.e., data loss before randomization, including 
patients missed by study procedures, identified but not approached, and those who declined 
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enrollment; and 2) post-inclusion attrition, or after randomization, consisting of drop-out, 
elimination, death, and intermittent attrition (missing PediQUEST survey [PQ-survey] 
opportunities during follow-up). 
To study pre-inclusion attrition, we: 1) screened all cancer deaths that occurred during the 
study period to detect patients who would have met eligibility criteria but were not identified 
through study procedures; 2) abstracted demographic and illness characteristics from medical 
records of all eligible patients; 3) tracked time from identification to enrollment/refusal; and 4) 
explored reasons for enrolling or declining through a paper-and-pencil “Consent Survey” 
administered on site or sent by mail to parents/legal guardians of all approached subjects 
immediately following initial contact. This 44-item survey, adapted from Tait et al. (26), 
assessed perceived appropriateness of the child’s inclusion, decisional effectiveness, privacy and 
time needed to make the decision, perceived study burden, and parent’s trust in the health care 
system and sense of altruism. Non-consenters received an abridged version. Consent 
documentation was waived. Families received a small non-monetary incentive. 
Post-inclusion attrition is reported for nine months, the original proposed follow-up. 
Specifically, we: 1) tracked drop-out, elimination (patients off treatment and in remission for six 
months), and death among enrollees; 2) explored reasons for staying (or not) in the study and 
satisfaction with participation using a paper-and-pencil 28-item “Participation Survey”, adapted 
from Janson et al. (27), and administered upon study completion, drop-out, or at least four 
months after the child’s death; 3) calculated intermittent attrition (IA) as number of PQ-surveys 
not administered over total number of eligible PQ-survey administration opportunities (eligible 
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PQ opportunities) overall and per month, and explored reasons for intermittent participation. 
Eligible PQ opportunities were identified through administrative records and defined based on 
study procedures (Fig. 1) as any clinic appointment with the oncologist, or any day during an 
admission, that was at least one week apart from the prior PQ-survey or eligible PQ opportunity. 
Patients who had no appointment or admission for over one month were assigned a monthly 
eligible PQ opportunity. Research staff recorded reasons for not administering a survey; an 
eligible PQ opportunity that was inadvertently missed was classified as a “missed opportunity.”  
To further inform the feasibility of routinely collecting patient-reported outcomes, we tracked 
respondent (patient/parent), completion time, and survey completeness.  
Statistical Analysis 
Descriptive statistics including frequencies and means or medians were used to 
summarize pre- and post-inclusion attrition. We explored whether gender, study arm, type of 
tumor, age, and survival were associated with attrition. We compared approached to not 
approached subjects and enrolled to non-enrolled subjects for pre-inclusion attrition; and dropout 
subjects to those who completed the study for post-inclusion attrition. Chi-square or Fisher's 
exact tests was used for categorical variables, and Wilcoxon rank-sum or t-test for numerical 
variables. We explored the relationship of IA with the covariates mentioned above, location 
(clinic visit, inpatient, home), and dropout status through univariate analysis. We also examined 
monthly variation of IA, aiming to identify an optimal follow-up time. We defined 40% IA as a 
recommended threshold following Judson et al. (28). Finally, we explored IA at end of life by 
analyzing eligible PQ opportunities during the last 12 weeks of life. All analyses were conducted 
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using SAS 9.2 (SAS Institute Inc., Cary, NC). 
Reasons to enroll and remain in the study were analyzed using qualitative methodology. 
Specifically, quantitative and qualitative data from the consent and participation surveys were 
combined into seldom convergence coding matrixes and used to conduct thematic coding and 
content analysis (29). 
Results  
Pre-Inclusion Attrition 
Using methods described in Fig. 1, we identified a total of 339 potentially eligible 
subjects over the five years the study was open (Fig. 2, Level B). Forty-three additional children 
who would have been eligible were identified through review of cancer deaths, representing the 
lower boundary for those missed by study procedures. Sixty-eight percent of identified patients 
were eligible; in 6%, we could not verify eligibility (Level C). Sensitive to patients’ conditions, 
the best time for inviting a family to participate in the study was agreed upon with primary 
providers. Of the 231 eligible patients, 64% were approached (Level D).  The most frequent 
reason for not making contact with families was that the child had died after being identified, but 
prior to contact. Seventy-one percent of those approached enrolled in the study (Level E) at an 
average rate of one patient per site per month. Median time from eligibility to enrollment was 39 
(interquartile range [IQR] 20-90) days. After 4.5 years of accrual, enrollment was closed at 104 
patients before reaching the target sample of 120 because we concluded that the cost of enrolling 
16 additional patients outweighed the information these patients would contribute. The reduction 
in proposed follow-up from nine to three months with re-enrollment opportunities, as 
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explained in Fig. 1, significantly increased recruitment rates from 58% to 77% (P=0.0147). This 
strategy did not increase the approach rate among patients who were going to die by nine months 
(after being identified), but their refusal rate, once approached, was lower (nine of 17 and one of 
13, respectively).  
Table 1 shows characteristics of all identified and eligible patients. No significant 
differences were observed between enrolled and not enrolled patients. Those approached for 
enrollment were similar to those “not approached” in all but two characteristics: type of cancer 
and survival. Patients not approached were less likely to have a hematological malignancy and 
more likely to have brain tumors (P=0.0051), and to die at three or six months after being 
identified (P<0.0001). Notably, the six-month death incidence of the 21 patients whose provider 
denied permission to approach was not significantly different to that of those approached (19% 
and 12%, respectively, P=0.3321). The 43 patients missed by study procedures (Fig. 2, Level B) 
had a mortality rate that was similar to that of the non-approached (21% and 52% at three and six 
months), and a larger prevalence of brain tumors (60%). 
Reasons to Enroll in or Decline the PediQUEST Study 
The consent survey was answered by 95 of 147 (65%) approached patients including 83 
of 104 (80%) enrolled subjects and 12 of 43 (28%) non-enrolled; 90% were parents (mostly 
mothers), 8% patients 18 years old or older, and 2% grandparents. Among those enrolled, 
respondents and non-respondents were comparable. Non-enrollee response rates varied highly by 
site (7%, 20%, and 88%), suggesting there were differences in administration strategies. Fig. 3, 
panel A presents respondents’ answers to selected items and reveals differences in how enrolled 
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and non-enrolled respondents understood the study, and perceived enrollment processes. 
Enrolled respondents mostly reported that quality of life studies were important, and their child 
was a good candidate for the study; they enrolled to help other families and give back to the 
institution. Qualitative analysis identified the following themes behind families’ decisions (Fig.  
3, panel B): enrollees reported enrolling because of the desire to “help other cancer patients and 
their families” (n=43), “improve care” (n=17), and “child’s wish to participate” (n=12); whereas 
non-enrollees most frequently cited that the “study involved too much time or effort” (n=6), and 
that the “child was not interested” (n=4).  
Post-Inclusion Attrition. Median duration of participation was 4.8 (IQR 2.7-9.0) months. 
Over nine months, 87 of 104 patients completed study requirements; of these, two were 
eliminated and 24 died. Fig. 2, Level F shows censoring across study arms and Fig. 4, the 
number of subjects at each time point by type of censoring. The higher death incidence in the 
intervention arm (Fig. 2-F) was unforeseen and likely related to chance (24).  
Seventeen patients dropped out; their median follow-up was 3.8 (IQR 1.8-5.9) months. 
Reasons for drop-out included: 1) patient not wanting to continue because in remission and off-
treatment (but not meeting elimination criteria) (n=6), 2) transfer of care to another institution 
(n=3); and 3) no reason stated (n=8). Two drop-out patients died by nine months. There were no 
significant differences between drop-outs and those who completed the study.  
Reasons to Stay in the PediQUEST Study 
 Of the 104 enrolled patients, 45% completed the participation survey. All but two 
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respondents were more than satisfied with participation. Lack of time (n=9) and child not having 
energy to fill-out the surveys (n=9) were the most commonly reported issues that challenged 
participation. When asked about the main factor that kept families enrolled in the study, the 
themes that emerged were “study was easy, no reason to stop” (n=14), “to help others” (n=13), 
“children enjoyed incentives” (n=10), and “study was relevant” (n=7). Respondents’ answers are 
also graphically summarized in Fig. 5 as a word cloud, i.e., a proportional representation of all 
open-ended responses obtained. When asked about researchers’ actions that helped participation, 
flexible study procedures and staff pleasantness were most frequently cited.  
Intermittent Attrition 
During the nine-month follow-up, 1669 eligible PQ opportunities were identified. Fig. 4 
area graph shows number of eligible PQ opportunities and survey administration status over 
time. Table 2 presents details of eligible PQ opportunities including administered and not 
administered surveys, and intermitent attrition. PediQUEST was administered 920 times (55%), 
a median of eight times per patient (IQR 4-12). Surveys were more likely to be administered 
when eligible PQ opportunities occurred in clinic (61%) than on the ward (40%), or home (13%) 
(P<0.0001). Only 2% of surveys were incomplete. Patients self-reported 94% of the time 
(adolescents 99%). Most “not administered” surveys were missed opportunities; when patients 
declined to answer surveys it was because of feeling ill (8%) or not being interested (7%). 
Monthly IA showed a two-phase plateau pattern: around 41% up to 20 weeks, jumping to 58% 
thereafter. IA was unrelated to gender, age, study arm, type of cancer, or drop-out.  
Regarding IA at end of life, of the 26 deaths, 25 patients completed at least one survey in 
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the last 12 weeks of life and had 165 eligible PQ opportunities over the nine-month period (Table 
2). Sixty-four surveys were administered (39%). Surveys were also more likely to be 
administered if the patient was in clinic. Reasons for not administering surveys (n=101) were 
similar to the whole sample. Median IA was 58% (IQR 50-80%) and increased as death 
approached. Half of the patients completed their last survey five weeks or less before death (IQR 
2-9). 
Discussion  
To our knowledge, this is the first report on the feasibility of conducting a multicenter 
longitudinal PPC RCT in children with advanced cancer. Although requiring enrollment to 
continue for five years, our results demonstrate that such RCTs are feasible: we reached a 
sufficient sample and were able to retain 84% of subjects; families welcomed the opportunity to 
participate and did so for altruistic reasons; children/teenagers were willing to self-report and 
longitudinal measurement showed acceptable intermittent attrition for up to 20 weeks of follow-
up. Strategies that helped us meet our goals included shortening the proposed follow-up (with 
optional re-enrollment), low burden study procedures, use of incentives, and research staff’s 
pleasantness and flexibility. Amidst this success, some challenges remain: not unlike those 
reported among adults (8, 11), pre-inclusion attrition was high and introduced selection bias; 
enrollment rate was low (one patient per site per month); and adherence with longitudinal data 
collection could be improved, especially at end of life. 
This was a pilot study with a limited target sample (n=120). Even so, and despite using 
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(as suggested in the literature (30)) comprehensive identification procedures and sensitive 
enrollment strategies, enrolling 104 patients took almost five years at three high-volume sites. 
Considering that most palliative care interventions have moderate effect sizes, an increase in 
enrollment capacity is imperative. Our results suggest that higher and faster enrollment could be 
achieved, at least partly, by devising strategies to increase the number of sicker patients 
approached, prevent exclusion of certain patient groups, and limit family refusals. 
About 20% of identified eligible patients (n=48) were clinically unstable and died a few 
months after being identified; at least a similar number (n=43) were missed by study procedures. 
Our recruitment procedures, which lead to a median of 39 days between eligibility and 
enrollment, may have limited sicker patients’ families’ opportunities to choose to participate. 
Expert opinion suggests that preventing participation of this relevant population might be 
unethical (8).  In our study, and consistent with a recent systematic review (19), participating 
families agreed that research was not burdensome or intrusive, and many reported they 
appreciated the opportunity to express their altruism. We observed that shortening the proposed 
follow-up improved accrual but not the approach of sicker patients. Approaching these patients 
can be difficult for research staff and be deemed inappropriate for IRBs and primary providers 
(8, 15). Strategies that may help recruit sicker patients include appropriate research staff training, 
using clinicians as recruiters, or using an advanced consent process, obtained at early stages of 
disease progression and put into effect later when the patient fully meets eligibility (15). 
Although overt provider gatekeeping was low (9%) and not associated with the patient’s 
clinical status, the fact that patients with specific diagnoses were less likely to be identified 
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or approached, and difficulties in verifying eligibility, suggest subtle gatekeeping behaviors that 
could account for up to 30% of pre-inclusion attrition. We did not explore providers’ reasons, but 
the literature suggests providers have reservations about palliative care research (15, 19). 
Gatekeeping may be reduced by educating providers about families’ perceptions of research 
participation, combined with department policies and professional associations’ statements(31) 
supporting palliative and supportive care research. 
Family refusals accounted for 16% of pre-inclusion attrition and seemed to be driven by 
parents’ views on the study and their child’s preference, and not related to illness. The low 
response rate among non-enrollees to the survey asking about their reasons for declining 
participation precluded further analyses. Drivers of refusal should be better understood to devise 
more effective recruitment strategies.   
Even if all these attrition sources were overcome, and assuming sicker patients may 
enroll at a lower rate, enrollment at most would have been increased to two patients per month 
per site, underscoring the necessity of multicenter efforts to increase the evidence base of PPC.  
Post-inclusion attrition was well within the expected range, below what has been 
previously reported (9, 15), and did not seem to introduce bias, but rather reflected typical paths 
in a palliative care study (8). Early enrollment has been proposed as a way of ensuring retention 
at end of life (30) and may have helped our high retention rates.  
Intermittent attrition up to the twentieth week of enrollment was around the 
recommended 40% threshold (28), possibly indicating an optimal follow-up period. Most of this 
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attrition, even at end of life, resulted from potentially reversible causes such as missed 
opportunities or other human factors, and occurred more when patients were at home or 
admitted. Web-based applications, which would allow for ubiquitous and flexible administration, 
may increase adherence and provide an ideal platform for multicenter studies. Research on the 
utility and implementation (32) of web tools may further increase feasibility of these RCTs.  
In conclusion, rigorous PPC research in children with advanced cancer is feasible, and 
most families are willing to participate, often for altruistic reasons. This study informs future 
research by providing estimates of enrollment and attrition and identifying successful 
recruitment and retention strategies. Successful PPC intervention studies in children with 
advanced cancer require, however, large multicenter studies. Research efforts and funding should 
move in this direction. 
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Figure Legends  
Fig. 1. Methods used in the Pediatric Quality of Life and Evaluation of Symptoms Technology 
(PediQUEST) Study – RCT Methods (adapted from Wolfe J et al.24).  1The PediQUEST-Survey 
(PQ-Survey) is an electronic survey that includes the adapted PediQUEST-Memorial Symptom 
Assessment Scale (PQ-MSAS, which evaluates symptom burden) and the Pediatric Quality of 
Life Inventory (PedsQL4.0, which evaluates quality of life). 
 
Fig. 2. The Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) 
Study flow diagram at nine months of follow-up. The Figure shows the sampling process and 
disposition at nine months of follow-up. Indicators used to study pre- and post-inclusion attrition 
are shown. Level A shows the target population; Level B: subjects missed and identified by 
study procedures; Level C: ineligible and eligible subjects; Level D: not approached and 
approached subjects; Level E: refused and enrolled; Level F: disposition at nine months of 
follow-up.  
 
Fig. 3. Families’ perceptions, values, and reasons to enroll in or decline the PediQUEST Study.  
Panel A shows perceptions of enrolled (83/104) and non-enrolled (12/43) families regarding 
study’s consent and decision-making processes, as well as values and reasons underlying their 
participation decision. Non-enrollees responded to an abridged survey version. Given the low 
non-enrolled response rate, no statistical testing was conducted. Only items with fewer than 10% 
missing values are graphed. Panel B presents reasons to enroll or not in the PediQUEST Study as 
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reported in open-ended questions (or quantitative items in the five surveys where comments were 
not provided). Over a third of respondents provided more than one reason. Representative quotes 
from enrolled and non-enrolled respondents are shown. 
 
Fig. 4. Disposition of patients enrolled in the PediQUEST Study over nine months of follow-up 
and feasibility of longitudinal assessment of electronic patient-reported outcomes. Line graph 
(top): number of study subjects available per week after censoring for: death (red line); death, 
drop-out, and elimination (green line); death, drop-out, elimination, and administrative 
censoring (black line). Area graph (bottom):  number of eligible PQ opportunities at each time 
point and the number that resulted in: an administered survey (green area), a not administered 
survey (purple) where reason for no administration was known; or a missed opportunity (light 
purple), i.e. opportunities that were inadvertently missed by research staff. 
 
Fig. 5. Reasons to stay enrolled in the PediQUEST randomized controlled study. This “word 
cloud” provides a proportional representation of all open-ended responses to the question 
“Which was the main factor that kept you in the (PediQUEST) study all the way?” Word size 
relates to the number of times the word appears. Graph built online using wordle.com 
application. 
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Table 1. Characteristics of 231 children with advanced cancer identified and eligible for the PediQUEST 
Randomized Controlled Study, by disposition status. 
 Approached for Enrollment 
(n=147) 
 Not 
approached 
(n=84) 
p valueb 
Enrolled 
(n=104) 
Not enrolled 
(n=43) 
p 
valuea 
All 
(n=147) 
  
 
 
No. % No. % 
 
No. % 
 
No. % 
 
Female  51  49 18 42 0.4276 69 47  29 35 0.0663 
Non-Hispanic White Race  92 88 33 77 0.0700 125 85  65 80 0.3533 
Child’s age (by groups)            
2-4 year-olds 16 15 3 7  19 13  15 18  
5-7 year-olds 15  15 9 21 0.5175 24 16  8 10 0.3734 
8-12 year-olds 23  22 9 21  32 22  17 20  
≥13 year-olds  50  48 22 51  72 49  44 52  
Diagnosis            
Hematological malignancies 36  34 14 33  50 34  18 22  
Brain Tumors 10  10 6 14 0.7436 16 11  22 26 0.0051 
Solid Tumors 58 56 23 53  81 55  44 52  
Deaths             
At 3 months from eligibility 4 4 5 12 0.1231c 9 6  30 36 <0.0001 
At 6 months from eligibility 11  11 6 14 0.5774 17 12  46 55 <0.0001 
a
 Chi2 tests (unless otherwise indicated) comparing enrolled vs. non-enrolled  
b
 Chi2 tests comparing approached vs. non-approached 
cFisher’s exact test 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2. Feasibility of longitudinal measurement of electronic patient reported 
outcomes in children enrolled in the PediQUEST Randomized Controlled Trial 
during 9-month follow-up and at end-of-life.  
 Eligible Opportunities 
 
All 
(n=1669) 
In last 12 weeks of life 
(n=165) 
Location No. % No. % 
Clinic  1364 82 99 60 
In-patient facilities 211 13 54 33 
Home 94 5 12 7 
Administered surveys 920 55 64 39 
Location     
Clinic 832 90 48 75 
In-patient facilities 84 9 14 22 
Home 12 1 2 3 
Incomplete surveys 18 2 5 8 
Administration time, in min      
Median 9.3 9.5 
IQR (6.0,15.4) (7.1, 17.8) 
Child self-report   
All children 777/826 94  49/55 89 
5-12 years old 321/367 88 16/23 70 
13 years old and over 456/459 99 31/32 97 
Not Administered surveys 749  45 101 61 
Reasons for no administration     
Missed opportunities 465  62 60 59 
Patient not available/unreachable 133 18 20  20 
Patient feeling too ill or upset 59  8 14  14 
Patient not interested 49 7 3 3 
Staff missed patient 37  5 4 4 
Technical problems 6 1 0 0 
Intermittent Attrition a    
All patients (weeks from study entry)   
Weeks 1-20   
Median 41  
IQR (36, 45)  
Weeks 21-39   
Median 58  
IQR (55, 62)  
At end of life (weeks before death)   
Weeks 12-9   
Median  45 
IQR  (38, 51) 
Weeks 8-5   
Median  65 
IQR  (60, 73) 
Weeks 4-1    
Median  73 
IQR  (58, 88) 
a Intermittent attrition: Proportion of PQ-surveys not administered over total number of PQ-survey 
administration opportunities that occurred during the indicated period. IQR: Interquartile range 
